Both THC-dominant and THC/CBD equivalent cannabis increased lane weaving during simulated driving but had little effect on other driving measures. Impairment on the Digit Symbol Substitution Task, Divided Attention Task, and Paced Auditory Serial Addition Task occurred with both active cannabis types, with worse performance on the latter two tasks after THC/CBD equivalent cannabis. Subjective feelings of being "stoned" and confidence in driving ability did not differ by CBD content. Peak plasma THC concentrations were higher after THC/CBD equivalent cannabis, suggesting a possible pharmacokinetic interaction. Cannabis with equivalent CBD and THC appears no less impairing than THC-dominant cannabis, and CBD may exacerbate THC-induced impairment in some circumstances.
Three-quarters of 254 mental health consumers surveyed in Australia expressed a desire to access psychedelic-assisted therapies (PATs) following government approval of MDMA for PTSD and psilocybin for treatment-resistant depression. Acceptability scores showed strong agreement about PAT effectiveness, moderate social endorsement, and mixed feelings about expected efficacy. While prior recreational psychedelic use was linked to higher acceptability, multivariate analysis revealed that intentions to access PAT were more strongly associated with higher acceptability scores and poorer experiences with conventional therapy. Consumers seeking alternatives to conventional treatment may view PATs as desirable despite safety reservations.